Showing results (141-150 of 157) with videos related to
Sort By:
Pageof 16
Cancer|January 17, 2018
Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinomaEileen M O'Reilly, Jonathan W Lee, Maeve A Lowery, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 17, 2018
Frequency of Germline Mutations in Cancer Susceptibility Genes in Malignant MesotheliomaVasiliki Panou, Meghana Gadiraju, Arthur Wolin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 4, 2015
Randomized Phase Ib/II Study of Gemcitabine Plus Placebo or Vismodegib, a Hedgehog Pathway Inhibitor, in Patients With Metastatic Pancreatic CancerDaniel V T Catenacci, Melissa R Junttila, Theodore Karrison, et al.British Journal of Cancer|October 7, 2021
Bevacizumab-induced hypertension and proteinuria: a genome-wide study of more than 1000 patientsJulia C F Quintanilha, Jin Wang, Alexander B Sibley, et al.Cancer Discovery|November 25, 2020
Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic DiseaseDaniel V T Catenacci, Stephanie Moya, Samantha Lomnicki, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 25, 2021
Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid TumorsCorey C Foster, Gini F Fleming, Theodore G Karrison, et al.JAMA Network Open|August 9, 2023
Germline Variants Incidentally Detected via Tumor-Only Genomic Profiling of Patients With MesotheliomaOwen D Mitchell, Katie Gilliam, Daniela Del Gaudio, et al.Plos One|August 15, 2018
The vitamin D receptor gene as a determinant of survival in pancreatic cancer patients: Genomic analysis and experimental validationFederico Innocenti, Kouros Owzar, Chen Jiang, et al.The Lancet. Oncology|March 31, 2022
Anetumab ravtansine versus vinorelbine in patients with relapsed, mesothelin-positive malignant pleural mesothelioma (ARCS-M): a randomised, open-label phase 2 trialHedy L Kindler, Silvia Novello, Alessandra Bearz, et al.Nature Medicine|November 9, 2021
Durvalumab with platinum-pemetrexed for unresectable pleural mesothelioma: survival, genomic and immunologic analyses from the phase 2 PrE0505 trialPatrick M Forde, Valsamo Anagnostou, Zhuoxin Sun, et al.Pageof 16